3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Melanoma
14
Uveal Melanoma
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Basal Cell
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Turcot syndrome
1
Tertiary Lymphoid Structures
1
Spinocerebellar Degenerations
1
Sarcoma
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Microsatellite Instability
1
Male Urogenital Diseases
1
Locally Advanced Melanoma
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Gastroesophageal Cancer
1
Interventions
padeliporfin
5
Nivolumab
3
vedolizumab
2
atezolizumab
2
anlotinib
2
Therapeutics
2
Surveys and Questionnaires
2
Riluzole
2
Radiotherapy
2
LDP-02
2
Ipilimumab
2
Infliximab
2
Immunoglobulin G
2
Genetic Testing
2
Fecal Microbiota Transplantation
2
Disulfides
2
Carboplatin
2
CT-P13
2
tislelizumab
1
relatlimab
1
prednylidene
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
olaparib
1
niraparib
1
ixabepilone
1
ferumoxtran-10
1
enfortumab vedotin
1
deltacortene
1
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urogenital Neoplasms
×
relatlimab
×
Clear all
NCT06237920
2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2
Recruiting
90 enrolled